GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Antibodies PLC (LSE:FAB) » Definitions » Price-to-Owner-Earnings

Fusion Antibodies (LSE:FAB) Price-to-Owner-Earnings : (As of Sep. 20, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Fusion Antibodies Price-to-Owner-Earnings?

As of today (2024-09-20), Fusion Antibodies's share price is £0.0325. Fusion Antibodies does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Fusion Antibodies's Price-to-Owner-Earnings or its related term are showing as below:


LSE:FAB's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 35.405
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-09-20), Fusion Antibodies's share price is £0.0325. Fusion Antibodies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was £-0.05. Therefore, Fusion Antibodies's PE Ratio for today is At Loss.

As of today (2024-09-20), Fusion Antibodies's share price is £0.0325. Fusion Antibodies's EPS without NRI for the trailing twelve months (TTM) ended in was £-0.05. Therefore, Fusion Antibodies's PE Ratio without NRI for today is At Loss.

During the past 10 years, Fusion Antibodies's highest PE Ratio without NRI was 10.54. The lowest was 0.00. And the median was 6.44.


Fusion Antibodies Price-to-Owner-Earnings Historical Data

The historical data trend for Fusion Antibodies's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Antibodies Price-to-Owner-Earnings Chart

Fusion Antibodies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Fusion Antibodies Semi-Annual Data
Mar15 Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Fusion Antibodies's Price-to-Owner-Earnings

For the Biotechnology subindustry, Fusion Antibodies's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fusion Antibodies's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fusion Antibodies's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Fusion Antibodies's Price-to-Owner-Earnings falls into.



Fusion Antibodies Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Fusion Antibodies's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.0325/-0.04
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fusion Antibodies  (LSE:FAB) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Fusion Antibodies Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Fusion Antibodies's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Fusion Antibodies Business Description

Traded in Other Exchanges
N/A
Address
1 Springbank Road, Springbank Industrial Estate, Dunmurry, Belfast, GBR, BT17 0QL
Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.

Fusion Antibodies Headlines

From GuruFocus

626 Financial, LLC Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor 10-21-2022